

Aaron Y Mochizuki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7695254/publications.pdf>

Version: 2024-02-01

27
papers

1,530
citations

1307366

7
h-index

1058333

14
g-index

28
all docs

28
docs citations

28
times ranked

2473
citing authors

#	ARTICLE	IF	CITATIONS
1	GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. <i>Nature</i> , 2022, 603, 934-941.	13.7	339
2	OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY. <i>Neuro-Oncology</i> , 2021, 23, i39-i39.	0.6	3
3	EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG. <i>Neuro-Oncology</i> , 2021, 23, i49-i50.	0.6	6
4	Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas. , 2021, , .		7
5	A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 744739.	1.3	5
6	IMMU-41. NEOADJUVANT PD-1 BLOCKADE INDUCES T CELL AND CDC1 ACTIVATION BUT FAILS TO OVERCOME THE IMMUNOSUPPRESSIVE TUMOR ASSOCIATED MACROPHAGES IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi101-vi101.	0.6	0
7	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <i>Nature Communications</i> , 2021, 12, 6938.	5.8	93
8	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	3.2	52
9	MBCL-14. A STUDY OF LOW-DOSE CRANIOSPINAL RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii390-iii391.	0.6	0
10	Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination. , 2020, , .		0
11	IMMU-20. SINGLE-CELL RNASEQ OF TUMOR INFILTRATING IMMUNE CELLS FROM NEOADJUVANT ANTI-PD1 TREATED GBM PATIENTS REVEALS GLOBAL TRANSCRIPTIONAL CHANGES AND IMMUNOSUPPRESSIVE ADAPTIVE RESPONSES BY MYELOID CELLS. <i>Neuro-Oncology</i> , 2020, 22, ii108-ii109.	0.6	0
12	IMMU-22. SINGLE-CELL CHARACTERIZATION OF INTRATUMORAL AND SYSTEMIC IMMUNE POPULATIONS IN PEDIATRIC AND ADULT BRAIN TUMORS REVEALS DIFFERENCES IN SUBPOPULATION COMPOSITION, ACTIVATION AND MEMORY. <i>Neuro-Oncology</i> , 2019, 21, ii97-ii97.	0.6	0
13	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
14	Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients. <i>Frontiers in Immunology</i> , 2019, 10, 121.	2.2	18
15	ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi4-vi5.	0.6	0
16	IMMU-02. NEOANTIGENS ARISING FROM ALTERNATIVE SPLICING EVENTS MAY BE TARGETED BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi118-vi119.	0.6	0
17	IMMU-33. IMMUNE PROFILING REVEALS INHIBITORY MACROPHAGES AND A DISTINCT SPATIAL DISTRIBUTION OF IMMUNE CELLS IN DIFFERENT TYPES OF BRAIN METASTASES. <i>Neuro-Oncology</i> , 2019, 21, vi126-vi126.	0.6	0
18	TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL. <i>Neuro-Oncology</i> , 2019, 21, vi248-vi248.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. <i>Clinical Cancer Research</i> , 2019, 25, 1913-1922.	3.2	57
20	Precision Medicine in Pediatric Neurooncology: A Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 11-28.	1.7	12
21	NCMP-10. AUTOIMMUNE ENCEPHALITIS IN POST-REMISSION PINEAL GERMINOMA: A CASE REPORT.. <i>Neuro-Oncology</i> , 2018, 20, vi195-vi196.	0.6	0
22	ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi3.	0.6	1
23	IMMU-21. MULTIDIMENSIONAL CHARACTERIZATION OF IMMUNE CELL POPULATIONS IN THE GLIOMA TUMOR MICROENVIRONMENT REVEALS A DOMINANT PROPORTION OF CELLS DERIVED FROM THE MYELO-MONOCYTIC LINEAGE. <i>Neuro-Oncology</i> , 2018, 20, vi125-vi125.	0.6	0
24	IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi127-vi127.	0.6	0
25	ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi6-vi6.	0.6	1
26	ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. <i>Neuro-Oncology</i> , 2018, 20, vi10-vi10.	0.6	1
27	Is Tel Hashomer camptodactyly a distinct clinical entity?. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 255-258.	0.7	2